MaxCyte (MXCT) to Release Quarterly Earnings on Wednesday

MaxCyte (NASDAQ:MXCT - Get Free Report) will post its quarterly earnings results after the market closes on Wednesday, November 6th. Analysts expect MaxCyte to post earnings of ($0.13) per share for the quarter. MaxCyte has set its FY 2024 guidance at EPS.Individual interested in registering for the company's earnings conference call can do so using this link.

MaxCyte (NASDAQ:MXCT - Get Free Report) last released its quarterly earnings results on Tuesday, August 6th. The company reported ($0.09) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.14) by $0.05. The business had revenue of $10.43 million for the quarter, compared to the consensus estimate of $8.20 million. MaxCyte had a negative net margin of 77.97% and a negative return on equity of 15.52%. During the same period in the previous year, the firm earned ($0.10) EPS. On average, analysts expect MaxCyte to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

MaxCyte Stock Performance

Shares of MaxCyte stock traded down $0.03 on Wednesday, reaching $3.54. The company had a trading volume of 279,453 shares, compared to its average volume of 507,705. The firm's 50 day moving average price is $3.92 and its two-hundred day moving average price is $4.19. The firm has a market cap of $372.30 million, a PE ratio of -10.41 and a beta of 1.39. MaxCyte has a 52-week low of $2.92 and a 52-week high of $5.55.

Insider Buying and Selling at MaxCyte

In other MaxCyte news, EVP Thomas M. Ross sold 15,476 shares of the company's stock in a transaction on Thursday, August 1st. The shares were sold at an average price of $4.54, for a total transaction of $70,261.04. Following the completion of the transaction, the executive vice president now owns 25,000 shares in the company, valued at approximately $113,500. This represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In other news, Director Stanley C. Erck sold 21,607 shares of the stock in a transaction dated Wednesday, October 2nd. The shares were sold at an average price of $3.71, for a total value of $80,161.97. Following the completion of the transaction, the director now owns 269,118 shares in the company, valued at $998,427.78. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, EVP Thomas M. Ross sold 15,476 shares of the stock in a transaction dated Thursday, August 1st. The shares were sold at an average price of $4.54, for a total transaction of $70,261.04. Following the completion of the transaction, the executive vice president now owns 25,000 shares of the company's stock, valued at $113,500. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders have sold 75,850 shares of company stock valued at $304,058. Insiders own 3.00% of the company's stock.

About MaxCyte

MaxCyte, Inc, a life sciences company, discovers, develops, and commercializes next-generation cell therapies in the United States and internationally. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering.